In Alzheimer’s disease, microglia act as a double-edged sword. They can either protect the brain or worsen the damage, depending on their activation state. Inflammatory activation harms healthy neurons. However, a study reveals that a special type of microglia expressing specific receptors and behaving like T cells may help mitigate this neurodegenerative condition. Read More

San Francisco Bay Area researchers from UC Berkeley, UC San Francisco and Stanford University have combined their technologies to create Azalea Therapeutics Inc., a company focused on editing cells in vivo. Read More

Genfit SA has established a research collaboration with Everzom SAS to expand its acute-on-chronic liver failure (ACLF) research via exosome-based regenerative technology. The partners plan to conduct exploratory studies to assess efficacy of Everzom’s investigational drug candidate Eviv in ACLF. Read More

CDR-Life Inc. has presented data on the preclinical characterization of CDR-111, a CD19/BCMA dual T-cell engager for treating autoimmune diseases. Read More

A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. Read More

Editor Annette Boyle discusses the challenges med-tech companies face in bringing innovation to market and how the industry can overcome them. Read More

Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Medicine Co. Ltd. have disclosed norbornene derivatives reported to be useful for the treatment of cerebral infarction, coronary heart disease, myocardial infarction and cerebral ischemia. Read More

Prospect Therapeutics Inc.’s PSTA-2413 is a newly developed oral pan-RAS inhibitor that demonstrates selectivity over wild-type KRAS, along with strong in vitro potency and in vivo antitumor efficacy. Read More

The Schlafen (SLFN) family of interferon-inducible genes, involved in the regulation of immune and antiviral responses, has recently attracted attention for the development of novel anticancer therapies. Read More

Aligos Therapeutics Inc. and Katholieke Universiteit Leuven (KU Leuken) have synthesized antiviral compounds reported to be useful for the treatment of coronavirus acute respiratory syndrome, norovirus and picornavirus infections. Read More

Petra Pharma Corp. has identified phosphatidylinositol 3-kinase α (PI3Kα) E545K and H1047R mutant inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum (PROS). Read More

Researchers from Chemdiv Inc. and Eilean Therapeutics LLC recently presented preclinical data on ZE77-0273, an AI-designed, reversible pan-EGFR inhibitor developed to address a key unmet need in the treatment of EGFR-mutant non-small-cell lung cancer. Read More

Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a pan-KRAS-targeting moiety through a linker. Read More

Sage Therapeutics Inc. has described sterol derivatives acting as glutamate receptor ionotropic, NMDA 2A (GRIN2A; GluN2A) negative allosteric modulators reported to be useful for the treatment of neurological disorders. Read More

Taxanes such as paclitaxel are among the standard chemotherapies for triple-negative breast cancer, one of the most aggressive forms of this tumor type. However, numerous processes can contribute to paclitaxel resistance. As a next-generation drug that could help overcome such resistance, researchers at six universities in China, including Ningxia Medical University, examined the crystal structure of protein arginine methyltransferase 1 (PRMT1) and developed, in silico, a pharmacophore that could bind tightly to it. PRMT1, which acts as an epigenetic regulator, is overexpressed in various cancers and its levels correlate inversely with survival. Read More

Researchers from Macrogenics Inc. presented preclinical efficacy data on MGC-026, an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody (MGA017) targeting B7-H3, linked to a cytotoxic exatecan payload via a cleavable Val-Ala-PABC linker using Synaffix Glycoconnect technology. Read More